Resveratrol nanosuspensions for dermal application - Production, characterization, and physical stability

Pharmazie

Volumn 64, Issue 11, 2009, Pages 741-747

  Kobierski, S ^a   Ofori Kwakye, K ^a   Muller R H ^a   Keck, Cornelia M ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

POLOXAMER; POLYSORBATE 80; RESVERATROL;

ARTICLE; DRUG FORMULATION; DRUG STABILITY; LASER DIFFRACTION; PARTICLE SIZE; PHOTON CORRELATION SPECTROSCOPY; ZETA POTENTIAL;

ADMINISTRATION, TOPICAL; ANTIOXIDANTS; CALORIMETRY, DIFFERENTIAL SCANNING; DRUG STABILITY; ELECTROCHEMISTRY; EXCIPIENTS; NANOPARTICLES; PARTICLE SIZE; SKIN ABSORPTION; STILBENES; SUSPENSIONS;

EID: 75749111422     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2009.9097     Document Type: Article

References (34)

1. Buckton G, Beezer AE (1992) The relationship between particle size and solubility. Int J Pharm 82: R7-R10.
2. Effendy I, Maibach HI (1995) Surfactants and experimental irritant contact dermatitis. Contact Dermatitis 33: 217-225.
3. Fichera MA et al. (2004) Effect of 4000 bar homogenisation pressure on particle diminution in drug suspensions. APV, Nürnberg.
4. Hecq J, Deleers M, Fanara D, Vranckx H, Amighi K (2005) Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine. Int J Pharm 299: 167-177.
5. Jang JH, Surh YJ (2001) Protective effects of resveratrol on hydrogen peroxide-induced apoptosis in rat pheochromocytoma (PC12) cells. Mutat Res 496: 181-190.
6. Jia L, Wong H, Cerna C, Wetman SD (2002) Effect of nanonization on absorption of 301029: ex vivo and in vivo pharmacokinetic correlations determined by liquid chromatography/mass spectrometry. Pharm Res 19: 1091-1096.
7. Karmarkar AB (2008) Poloxamers and their applications, Pharmacy Student Articles.
8. Keck CM (2008) NanoCrystal® Technology: A formulation approach for poorly water soluble Compounds. Particle Design for APIs and Drug Products, Brussels.
9. Keck CM, Müller RH (2006) Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm 62: 3-16.
10. Keck CM, Müller RH (2008) Nanodiamanten - Erhöhte Bioaktivitat. Labor & More 01/0864-65.
11. Kobierski S et al. (2008) Production of Hesperidin dermal nanocrystals by novel smartCrystal combination technology. European Workshop on Particulate Systems, Berlin.
12. Liversidge GG, Cundy KC (1995) Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm 125: 91-97.
13. Liversidge GG et al. (1992) Surface modified drug nanoparticles. United States Patent 5,145,684.
14. Mehling A, Kleber M, Hensen H (2007) Comparative studies on the ocular and dermal irritation potential of surfactants. Food Chem. Toxicol 45: 747-758.
15. Mosharraf M, Nystrom C (2003) Apparent solubility of drugs in partially crystalline systems. Drug Dev Ind Pharm 29: 603-622.
16. Müller RH (1996) Zetapotential und Partikelladung in der Laborpraxis. Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart.
17. Müller RH et al. (1999a) Pharmaceutical nanosuspensions for medicament administration as systems with increased saturation solubility and rate of solution. United States Patent 5,858,410.
18. Müller RH et al. (1999b) Pharmaceutical nanosuspensions for medicament administration as systems with increased saturation solubility and rate of solution. United States Patent 5,858,410.
19. Müller RH et al. (2007) Rutin drug nanocrystals for dermal cosmetic application. AAPS Annual Meeting, San Diego.
20. Müller RH, Heinemann S (1991) Photon correlation spectroscopy and zeta potential characterization of model particles and colloidal drug carriersessential information for the interpretation of cell culture studies. Biochem Soc Trans 19: 502.
21. Müller RH et al. (2003) DissoCubes - a novel formulation for poorly soluble and poorly bioavailable drugs. In: Rathbone MJ, Hadgraft J et al. (ed.), Modified-Release Drug Delivery Systems, ed., pp. 135-149.
22. Müller RH, Junghanns J-U (2006) Drug nanocrystals/nanosuspensions for the delivery of poorly soluble drugs. In: Torchilin VP (ed.), Nanoparticulates as Drug Carriers, 1 ed., London, pp. 307-328.
23. Müller RH, Keck CM (2004) Challenges and solutions for the delivery of biotech drugs-a review of drug nanocrystal technology and lipid nanoparticles. J Biotechnol 113: 151-170.
24. Müller RH et al. (2000) Verfahren zur schonenden Herstellung von hochfeinen Micro-/Nanopartikeln. PCT Application PCT/EP00/06535.
25. Petersen RD (2006) Nanocrystals for use in topical formulations and method of production thereof. PCT/EP2007/009943.
26. Piao H, Kamiya N, Hirata A, Fujii T, Goto M (2008) A novel solid-in-oil nanosuspension for transdermal delivery of diclofenac sodium. Pharm Res 25: 896-901.
27. Rabinow B, Kipp J, Papadopoulos P, Wong J, Glosson J, Gass J, Sun CS, Wielgos T, White R, Cook C, Barker K, Wood K (2007) Itraconazole IV nanosuspension enhances efficacy through altered pharmacokinetics in the rat. Int J Pharm 339: 251-260.
28. Rabinow BE (2004) Nanosuspensions in drug delivery. Nat Rev Drug Discov 3: 785-796.
29. Renaud S, de Lorgeril M (1992) Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 339: 1523-1526.
30. Renaud S, de Lorgeril M (1993) The French paradox: dietary factors and cigarette smoking-related health risks. Ann N YAcad Sci 68: 6299-309.
31. st ed., Malden, pp. 208-222.
32. Renaud S, Ruf JC (1994) The French paradox: vegetables or wine. Circulation 90: 3118-3119.
33. st ed., Berlin, Heidelberg, pp. 1-39.
34. Sun J, Simon SL (2007) The melting behavior of aluminum nanoparticles. Thermochim Acta 463: 32-40.